Search research articles
Contact Us
Filters
Showing results (331-340 of 362) with videos related to
Page
of 37
Sort By:
The Lancet. Oncology
|
April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, et al.
JAMA Oncology
|
April 10, 2020
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, et al.
Future Oncology (London, England)
|
March 25, 2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
JTO Clinical and Research Reports
|
May 27, 2022
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
Christine M Bestvina, Jennifer G Whisenant, Valter Torri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 22, 2018
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort
Undine Rulle, Zoi Tsourti, Ruben Casanova, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Vivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
Lancet (London, England)
|
February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trial
Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 28, 2019
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project
Keith M Kerr, Erik Thunnissen, Urania Dafni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2017
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
Igor Letovanec, Stephen Finn, Panagiota Zygoura, et al.
The Lancet. Respiratory Medicine
|
April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Page
of 37
Search research articles
Search
Showing results (331-340 of 362) with videos related to
Sort By:
Page
of 37
The Lancet. Oncology
|
April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
José Trigo, Vivek Subbiah, Benjamin Besse, et al.
JAMA Oncology
|
April 10, 2020
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, et al.
Future Oncology (London, England)
|
March 25, 2025
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
JTO Clinical and Research Reports
|
May 27, 2022
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
Christine M Bestvina, Jennifer G Whisenant, Valter Torri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 22, 2018
Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort
Undine Rulle, Zoi Tsourti, Ruben Casanova, et al.
Lung Cancer (Amsterdam, Netherlands)
|
October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Vivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.
Lancet (London, England)
|
February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trial
Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 28, 2019
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project
Keith M Kerr, Erik Thunnissen, Urania Dafni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2017
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
Igor Letovanec, Stephen Finn, Panagiota Zygoura, et al.
The Lancet. Respiratory Medicine
|
April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Page
of 37